Exact Mass: 575.2829

Ergokryptine

C32H41N5O5 (575.3108)

D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists

beta-Ergocryptine

C32H41N5O5 (575.3108)

alpha-Ergocryptine in which the isobutyl (2-methylpropyl) substituent is replaced by sec-butyl (1-methylpropyl). It is a natural ergot alkaloid. Note that ergocryptine discussed in the literature prior to 1967, when beta-ergocryptine was separated from alpha-ergocryptine, is now referred to as alpha-ergocryptine.

Mauritine A

C32H41N5O5 (575.3108)

Mauritine A is found in fruits. Mauritine A is an alkaloid from the stem bark of Zizyphus jujuba (Chinese date

Ergokryptine

C32H41N5O5 (575.3108)

Pro-phe-arg-mca

C30H37N7O5 (575.2856)

PC(2:0/18:2(10E,12Z)+=O(9))

C28H50NO9P (575.3223)

PC(2:0/18:2(10E,12Z)+=O(9)) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/18:2(10E,12Z)+=O(9)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 9-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

PC(18:2(10E,12Z)+=O(9)/2:0)

C28H50NO9P (575.3223)

PC(18:2(10E,12Z)+=O(9)/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(18:2(10E,12Z)+=O(9)/2:0), in particular, consists of one chain of one 9-oxo-octadecadienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

PC(2:0/18:2(9Z,11E)+=O(13))

C28H50NO9P (575.3223)

PC(2:0/18:2(9Z,11E)+=O(13)) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/18:2(9Z,11E)+=O(13)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 13-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

PC(18:2(9Z,11E)+=O(13)/2:0)

C28H50NO9P (575.3223)

PC(18:2(9Z,11E)+=O(13)/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(18:2(9Z,11E)+=O(13)/2:0), in particular, consists of one chain of one 13-oxo-octadecadienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

PC(2:0/18:3(10,12,15)-OH(9))

C28H50NO9P (575.3223)

PC(2:0/18:3(10,12,15)-OH(9)) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/18:3(10,12,15)-OH(9)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 9-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

PC(18:3(10,12,15)-OH(9)/2:0)

C28H50NO9P (575.3223)

PC(18:3(10,12,15)-OH(9)/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(18:3(10,12,15)-OH(9)/2:0), in particular, consists of one chain of one 9-hydroxyoctadecatrienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

PC(2:0/18:3(9,11,15)-OH(13))

C28H50NO9P (575.3223)

PC(2:0/18:3(9,11,15)-OH(13)) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/18:3(9,11,15)-OH(13)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 13-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

PC(18:3(9,11,15)-OH(13)/2:0)

C28H50NO9P (575.3223)

PC(18:3(9,11,15)-OH(13)/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(18:3(9,11,15)-OH(13)/2:0), in particular, consists of one chain of one 13-hydroxyoctadecatrienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

O-12-Methylergocornine

C32H41N5O5 (575.3108)

foroxymithine

C22H37N7O11 (575.2551)

Detoxin D3

C30H45N3O8 (575.3206)

Detoxin D4

C30H45N3O8 (575.3206)

19-Oxofasciospongine A

C30H45N3O6S (575.3029)

5-epi-beta-Ergocryptine

C32H41N5O5 (575.3108)

MFO-1

C25H45N5O10 (575.3166)

Gentamicin Sulfate, 100X Solution

C21H45N5O11S (575.2836)

scutehenanine C

C33H37NO8 (575.2519)

leiodolide A

C31H45NO9 (575.3094)

viridiofungin B

C31H45NO9 (575.3094)

Anthraserpine

C32H37N3O7 (575.2631)

Nargenicin C1

C30H41NO10 (575.273)

scutehenanine B

C33H37NO8 (575.2519)

His Glu Tyr Lys

C26H37N7O8 (575.2703)

Glu Met Leu Val Ala

C25H45N5O8S (575.2989)

Asp Thr Val Ile Glu

C24H41N5O11 (575.2802)

Thr His Tyr Arg

C25H37N9O7 (575.2816)

alpha-Ergocryptine

C32H41N5O5 (575.3108)

Ergotaman bearing hydroxy, isopropyl, and 2-methylpropyl groups at the 12, 2 and 5 positions, respectively, and oxo groups at positions 3, 6, and 18. It is a natural ergot alkaloid. Ergocryptine discussed in the literature prior to 1967, when beta-ergocryptine was separated from alpha-ergocryptine, is now referred to as alpha-ergocryptine. D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists relative retention time with respect to 9-anthracene Carboxylic Acid is 1.085 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.083 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.081 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.080

5-[[4-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentanoic acid

C25H45N5O10 (575.3166)

ergocryptine

C32H41N5O5 (575.3108)

D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists CONFIDENCE Claviceps purpurea sclerotia

5-[[4-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentanoic acid

C25H45N5O10 (575.3166)

Gentamicin sulfate

C21H45N5O11S (575.2836)

Ergocryptinine

C32H41N5O5 (575.3108)

CONFIDENCE Reference Standard (Level 1)

5-[[4-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentanoic acid_major

C25H45N5O10 (575.3166)

Ala His Trp Tyr

C29H33N7O6 (575.2492)

Ala His Tyr Trp

C29H33N7O6 (575.2492)

Ala Asn Trp Trp

C29H33N7O6 (575.2492)

Ala Trp His Tyr

C29H33N7O6 (575.2492)

Ala Trp Asn Trp

C29H33N7O6 (575.2492)

Ala Trp Trp Asn

C29H33N7O6 (575.2492)

Ala Trp Tyr His

C29H33N7O6 (575.2492)

Ala Tyr His Trp

C29H33N7O6 (575.2492)

Ala Tyr Trp His

C29H33N7O6 (575.2492)

Asp Lys Lys Trp

C27H41N7O7 (575.3067)

Asp Lys Gln Trp

C26H37N7O8 (575.2703)

Asp Lys Trp Lys

C27H41N7O7 (575.3067)

Asp Lys Trp Gln

C26H37N7O8 (575.2703)

Asp Gln Lys Trp

C26H37N7O8 (575.2703)

Asp Gln Trp Lys

C26H37N7O8 (575.2703)

Asp Trp Lys Lys

C27H41N7O7 (575.3067)

Asp Trp Lys Gln

C26H37N7O8 (575.2703)

Asp Trp Gln Lys

C26H37N7O8 (575.2703)

Glu Glu Ile Trp

C27H37N5O9 (575.2591)

Glu Glu Leu Trp

C27H37N5O9 (575.2591)

Glu Glu Trp Ile

C27H37N5O9 (575.2591)

Glu Glu Trp Leu

C27H37N5O9 (575.2591)

Glu His Lys Tyr

C26H37N7O8 (575.2703)

Glu His Tyr Lys

C26H37N7O8 (575.2703)

Glu Ile Glu Trp

C27H37N5O9 (575.2591)

Glu Ile Trp Glu

C27H37N5O9 (575.2591)

Glu Lys His Tyr

C26H37N7O8 (575.2703)

Glu Lys Asn Trp

C26H37N7O8 (575.2703)

Glu Lys Trp Asn

C26H37N7O8 (575.2703)

Glu Lys Tyr His

C26H37N7O8 (575.2703)

Glu Leu Glu Trp

C27H37N5O9 (575.2591)

Glu Leu Trp Glu

C27H37N5O9 (575.2591)

Glu Asn Lys Trp

C26H37N7O8 (575.2703)

Glu Asn Trp Lys

C26H37N7O8 (575.2703)

Glu Trp Glu Ile

C27H37N5O9 (575.2591)

Glu Trp Glu Leu

C27H37N5O9 (575.2591)

Glu Trp Ile Glu

C27H37N5O9 (575.2591)

Glu Trp Lys Asn

C26H37N7O8 (575.2703)

Glu Trp Leu Glu

C27H37N5O9 (575.2591)

Glu Trp Asn Lys

C26H37N7O8 (575.2703)

Glu Tyr His Lys

C26H37N7O8 (575.2703)

Glu Tyr Lys His

C26H37N7O8 (575.2703)

Phe His Ser Trp

C29H33N7O6 (575.2492)

Phe His Trp Ser

C29H33N7O6 (575.2492)

Phe Ser His Trp

C29H33N7O6 (575.2492)

Phe Ser Trp His

C29H33N7O6 (575.2492)

Phe Trp His Ser

C29H33N7O6 (575.2492)

Phe Trp Ser His

C29H33N7O6 (575.2492)

Gly Lys Trp Trp

C30H37N7O5 (575.2856)

Gly Gln Trp Trp

C29H33N7O6 (575.2492)

Gly Trp Lys Trp

C30H37N7O5 (575.2856)

Gly Trp Gln Trp

C29H33N7O6 (575.2492)

Gly Trp Trp Lys

C30H37N7O5 (575.2856)

Gly Trp Trp Gln

C29H33N7O6 (575.2492)

His Ala Trp Tyr

C29H33N7O6 (575.2492)

His Ala Tyr Trp

C29H33N7O6 (575.2492)

His Glu Lys Tyr

C26H37N7O8 (575.2703)

His Phe Ser Trp

C29H33N7O6 (575.2492)

His Phe Trp Ser

C29H33N7O6 (575.2492)

His His Pro Trp

C28H33N9O5 (575.2605)

His His Trp Pro

C28H33N9O5 (575.2605)

His Lys Glu Tyr

C26H37N7O8 (575.2703)

His Lys Tyr Glu

C26H37N7O8 (575.2703)

His Pro His Trp

C28H33N9O5 (575.2605)

His Pro Trp His

C28H33N9O5 (575.2605)

His Arg Thr Tyr

C25H37N9O7 (575.2816)

His Arg Tyr Thr

C25H37N9O7 (575.2816)

His Ser Phe Trp

C29H33N7O6 (575.2492)

His Ser Trp Phe

C29H33N7O6 (575.2492)

His Thr Arg Tyr

C25H37N9O7 (575.2816)

His Thr Tyr Arg

C25H37N9O7 (575.2816)

His Trp Ala Tyr

C29H33N7O6 (575.2492)

His Trp Phe Ser

C29H33N7O6 (575.2492)

His Trp His Pro

C28H33N9O5 (575.2605)

His Trp Pro His

C28H33N9O5 (575.2605)

His Trp Ser Phe

C29H33N7O6 (575.2492)

His Trp Tyr Ala

C29H33N7O6 (575.2492)

His Tyr Ala Trp

C29H33N7O6 (575.2492)

His Tyr Glu Lys

C26H37N7O8 (575.2703)

His Tyr Lys Glu

C26H37N7O8 (575.2703)

His Tyr Arg Thr

C25H37N9O7 (575.2816)

His Tyr Thr Arg

C25H37N9O7 (575.2816)

His Tyr Trp Ala

C29H33N7O6 (575.2492)

Ile Glu Glu Trp

C27H37N5O9 (575.2591)

Ile Glu Trp Glu

C27H37N5O9 (575.2591)

Ile Trp Glu Glu

C27H37N5O9 (575.2591)

Lys Asp Lys Trp

C27H41N7O7 (575.3067)

Lys Asp Gln Trp

C26H37N7O8 (575.2703)

Lys Asp Trp Lys

C27H41N7O7 (575.3067)

Lys Asp Trp Gln

C26H37N7O8 (575.2703)

Lys Glu His Tyr

C26H37N7O8 (575.2703)

Lys Glu Asn Trp

C26H37N7O8 (575.2703)

Lys Glu Trp Asn

C26H37N7O8 (575.2703)

Lys Glu Tyr His

C26H37N7O8 (575.2703)

Lys Gly Trp Trp

C30H37N7O5 (575.2856)

Lys His Glu Tyr

C26H37N7O8 (575.2703)

Lys His Tyr Glu

C26H37N7O8 (575.2703)

Lys Lys Asp Trp

C27H41N7O7 (575.3067)

Lys Lys Trp Asp

C27H41N7O7 (575.3067)

Lys Asn Glu Trp

C26H37N7O8 (575.2703)

Lys Asn Trp Glu

C26H37N7O8 (575.2703)

Lys Gln Asp Trp

C26H37N7O8 (575.2703)

Lys Gln Trp Asp

C26H37N7O8 (575.2703)

Lys Arg Ser Trp

C26H41N9O6 (575.318)

Lys Arg Trp Ser

C26H41N9O6 (575.318)

Lys Ser Arg Trp

C26H41N9O6 (575.318)

Lys Ser Trp Arg

C26H41N9O6 (575.318)

Lys Trp Asp Lys

C27H41N7O7 (575.3067)

Lys Trp Asp Gln

C26H37N7O8 (575.2703)

Lys Trp Glu Asn

C26H37N7O8 (575.2703)

Lys Trp Gly Trp

C30H37N7O5 (575.2856)

Lys Trp Lys Asp

C27H41N7O7 (575.3067)

Lys Trp Asn Glu

C26H37N7O8 (575.2703)

Lys Trp Gln Asp

C26H37N7O8 (575.2703)

Lys Trp Arg Ser

C26H41N9O6 (575.318)

Lys Trp Ser Arg

C26H41N9O6 (575.318)

Lys Trp Trp Gly

C30H37N7O5 (575.2856)

Lys Tyr Glu His

C26H37N7O8 (575.2703)

Lys Tyr His Glu

C26H37N7O8 (575.2703)

Leu Glu Glu Trp

C27H37N5O9 (575.2591)

Leu Glu Trp Glu

C27H37N5O9 (575.2591)

Leu Trp Glu Glu

C27H37N5O9 (575.2591)

Met Asn Arg Arg

C21H41N11O6S (575.2962)

Met Arg Asn Arg

C21H41N11O6S (575.2962)

Met Arg Arg Asn

C21H41N11O6S (575.2962)

Asn Ala Trp Trp

C29H33N7O6 (575.2492)

Asn Glu Lys Trp

C26H37N7O8 (575.2703)

Asn Glu Trp Lys

C26H37N7O8 (575.2703)

Asn Lys Glu Trp

C26H37N7O8 (575.2703)

Asn Lys Trp Glu

C26H37N7O8 (575.2703)

Asn Met Arg Arg

C21H41N11O6S (575.2962)

Asn Arg Met Arg

C21H41N11O6S (575.2962)

Asn Arg Arg Met

C21H41N11O6S (575.2962)

Asn Arg Thr Trp

C25H37N9O7 (575.2816)

Asn Arg Trp Thr

C25H37N9O7 (575.2816)

Asn Thr Arg Trp

C25H37N9O7 (575.2816)

Asn Thr Trp Arg

C25H37N9O7 (575.2816)

Asn Trp Ala Trp

C29H33N7O6 (575.2492)

Asn Trp Glu Lys

C26H37N7O8 (575.2703)

Asn Trp Lys Glu

C26H37N7O8 (575.2703)

Asn Trp Arg Thr

C25H37N9O7 (575.2816)

Asn Trp Thr Arg

C25H37N9O7 (575.2816)

Asn Trp Trp Ala

C29H33N7O6 (575.2492)

Pro His His Trp

C28H33N9O5 (575.2605)

Pro His Trp His

C28H33N9O5 (575.2605)

Pro Trp His His

C28H33N9O5 (575.2605)

Gln Asp Lys Trp

C26H37N7O8 (575.2703)

Gln Asp Trp Lys

C26H37N7O8 (575.2703)

Gln Gly Trp Trp

C29H33N7O6 (575.2492)

Gln Lys Asp Trp

C26H37N7O8 (575.2703)

Gln Lys Trp Asp

C26H37N7O8 (575.2703)

Gln Arg Ser Trp

C25H37N9O7 (575.2816)

Gln Arg Trp Ser

C25H37N9O7 (575.2816)

Gln Ser Arg Trp

C25H37N9O7 (575.2816)

Gln Ser Trp Arg

C25H37N9O7 (575.2816)

Gln Trp Asp Lys

C26H37N7O8 (575.2703)

Gln Trp Gly Trp

C29H33N7O6 (575.2492)

Gln Trp Lys Asp

C26H37N7O8 (575.2703)

Gln Trp Arg Ser

C25H37N9O7 (575.2816)

Gln Trp Ser Arg

C25H37N9O7 (575.2816)

Gln Trp Trp Gly

C29H33N7O6 (575.2492)

Arg His Thr Tyr

C25H37N9O7 (575.2816)

Arg His Tyr Thr

C25H37N9O7 (575.2816)

Arg Lys Ser Trp

C26H41N9O6 (575.318)

Arg Lys Trp Ser

C26H41N9O6 (575.318)

Arg Met Asn Arg

C21H41N11O6S (575.2962)

Arg Met Arg Asn

C21H41N11O6S (575.2962)

Arg Asn Met Arg

C21H41N11O6S (575.2962)

Arg Asn Arg Met

C21H41N11O6S (575.2962)

Arg Asn Thr Trp

C25H37N9O7 (575.2816)

Arg Asn Trp Thr

C25H37N9O7 (575.2816)

Arg Gln Ser Trp

C25H37N9O7 (575.2816)

Arg Gln Trp Ser

C25H37N9O7 (575.2816)

Arg Arg Met Asn

C21H41N11O6S (575.2962)

Arg Arg Asn Met

C21H41N11O6S (575.2962)

Arg Ser Lys Trp

C26H41N9O6 (575.318)

Arg Ser Gln Trp

C25H37N9O7 (575.2816)

Arg Ser Trp Lys

C26H41N9O6 (575.318)

Arg Ser Trp Gln

C25H37N9O7 (575.2816)

Arg Thr His Tyr

C25H37N9O7 (575.2816)

Arg Thr Asn Trp

C25H37N9O7 (575.2816)

Arg Thr Trp Asn

C25H37N9O7 (575.2816)

Arg Thr Tyr His

C25H37N9O7 (575.2816)

Arg Trp Lys Ser

C26H41N9O6 (575.318)

Arg Trp Asn Thr

C25H37N9O7 (575.2816)

Arg Trp Gln Ser

C25H37N9O7 (575.2816)

Arg Trp Ser Lys

C26H41N9O6 (575.318)

Arg Trp Ser Gln

C25H37N9O7 (575.2816)

Arg Trp Thr Asn

C25H37N9O7 (575.2816)

Arg Tyr His Thr

C25H37N9O7 (575.2816)

Arg Tyr Thr His

C25H37N9O7 (575.2816)

Ser Phe His Trp

C29H33N7O6 (575.2492)

Ser Phe Trp His

C29H33N7O6 (575.2492)

Ser His Phe Trp

C29H33N7O6 (575.2492)

Ser His Trp Phe

C29H33N7O6 (575.2492)

Ser Lys Arg Trp

C26H41N9O6 (575.318)

Ser Lys Trp Arg

C26H41N9O6 (575.318)

Ser Gln Arg Trp

C25H37N9O7 (575.2816)

Ser Gln Trp Arg

C25H37N9O7 (575.2816)

Ser Arg Lys Trp

C26H41N9O6 (575.318)

Ser Arg Gln Trp

C25H37N9O7 (575.2816)

Ser Arg Trp Lys

C26H41N9O6 (575.318)

Ser Arg Trp Gln

C25H37N9O7 (575.2816)

Ser Trp Phe His

C29H33N7O6 (575.2492)

Ser Trp His Phe

C29H33N7O6 (575.2492)

Ser Trp Lys Arg

C26H41N9O6 (575.318)

Ser Trp Gln Arg

C25H37N9O7 (575.2816)

Ser Trp Arg Lys

C26H41N9O6 (575.318)

Ser Trp Arg Gln

C25H37N9O7 (575.2816)

Thr His Arg Tyr

C25H37N9O7 (575.2816)

Thr Asn Arg Trp

C25H37N9O7 (575.2816)

Thr Asn Trp Arg

C25H37N9O7 (575.2816)

Thr Arg His Tyr

C25H37N9O7 (575.2816)

Thr Arg Asn Trp

C25H37N9O7 (575.2816)

Thr Arg Trp Asn

C25H37N9O7 (575.2816)

Thr Arg Tyr His

C25H37N9O7 (575.2816)

Thr Trp Asn Arg

C25H37N9O7 (575.2816)

Thr Trp Arg Asn

C25H37N9O7 (575.2816)

Thr Tyr His Arg

C25H37N9O7 (575.2816)

Thr Tyr Arg His

C25H37N9O7 (575.2816)

Trp Ala His Tyr

C29H33N7O6 (575.2492)

Trp Ala Asn Trp

C29H33N7O6 (575.2492)

Trp Ala Trp Asn

C29H33N7O6 (575.2492)

Trp Ala Tyr His

C29H33N7O6 (575.2492)

Trp Asp Lys Lys

C27H41N7O7 (575.3067)

Trp Asp Lys Gln

C26H37N7O8 (575.2703)

Trp Asp Gln Lys

C26H37N7O8 (575.2703)

Trp Glu Glu Ile

C27H37N5O9 (575.2591)

Trp Glu Glu Leu

C27H37N5O9 (575.2591)

Trp Glu Ile Glu

C27H37N5O9 (575.2591)

Trp Glu Lys Asn

C26H37N7O8 (575.2703)

Trp Glu Leu Glu

C27H37N5O9 (575.2591)

Trp Glu Asn Lys

C26H37N7O8 (575.2703)

Trp Phe His Ser

C29H33N7O6 (575.2492)

Trp Phe Ser His

C29H33N7O6 (575.2492)

Trp Gly Lys Trp

C30H37N7O5 (575.2856)

Trp Gly Gln Trp

C29H33N7O6 (575.2492)

Trp Gly Trp Lys

C30H37N7O5 (575.2856)

Trp Gly Trp Gln

C29H33N7O6 (575.2492)

Trp His Ala Tyr

C29H33N7O6 (575.2492)

Trp His Phe Ser

C29H33N7O6 (575.2492)

Trp His His Pro

C28H33N9O5 (575.2605)

Trp His Pro His

C28H33N9O5 (575.2605)

Trp His Ser Phe

C29H33N7O6 (575.2492)

Trp His Tyr Ala

C29H33N7O6 (575.2492)

Trp Ile Glu Glu

C27H37N5O9 (575.2591)

Trp Lys Asp Lys

C27H41N7O7 (575.3067)

Trp Lys Asp Gln

C26H37N7O8 (575.2703)

Trp Lys Glu Asn

C26H37N7O8 (575.2703)

Trp Lys Gly Trp

C30H37N7O5 (575.2856)

Trp Lys Lys Asp

C27H41N7O7 (575.3067)

Trp Lys Asn Glu

C26H37N7O8 (575.2703)

Trp Lys Gln Asp

C26H37N7O8 (575.2703)

Trp Lys Arg Ser

C26H41N9O6 (575.318)

Trp Lys Ser Arg

C26H41N9O6 (575.318)

Trp Lys Trp Gly

C30H37N7O5 (575.2856)

Trp Leu Glu Glu

C27H37N5O9 (575.2591)

Trp Asn Ala Trp

C29H33N7O6 (575.2492)

Trp Asn Glu Lys

C26H37N7O8 (575.2703)

Trp Asn Lys Glu

C26H37N7O8 (575.2703)

Trp Asn Arg Thr

C25H37N9O7 (575.2816)

Trp Asn Thr Arg

C25H37N9O7 (575.2816)

Trp Asn Trp Ala

C29H33N7O6 (575.2492)

Trp Pro His His

C28H33N9O5 (575.2605)

Trp Gln Asp Lys

C26H37N7O8 (575.2703)

Trp Gln Gly Trp

C29H33N7O6 (575.2492)

Trp Gln Lys Asp

C26H37N7O8 (575.2703)

Trp Gln Arg Ser

C25H37N9O7 (575.2816)

Trp Gln Ser Arg

C25H37N9O7 (575.2816)

Trp Gln Trp Gly

C29H33N7O6 (575.2492)

Trp Arg Lys Ser

C26H41N9O6 (575.318)

Trp Arg Asn Thr

C25H37N9O7 (575.2816)

Trp Arg Gln Ser

C25H37N9O7 (575.2816)

Trp Arg Ser Lys

C26H41N9O6 (575.318)

Trp Arg Ser Gln

C25H37N9O7 (575.2816)

Trp Arg Thr Asn

C25H37N9O7 (575.2816)

Trp Ser Phe His

C29H33N7O6 (575.2492)

Trp Ser His Phe

C29H33N7O6 (575.2492)

Trp Ser Lys Arg

C26H41N9O6 (575.318)

Trp Ser Gln Arg

C25H37N9O7 (575.2816)

Trp Ser Arg Lys

C26H41N9O6 (575.318)

Trp Ser Arg Gln

C25H37N9O7 (575.2816)

Trp Thr Asn Arg

C25H37N9O7 (575.2816)

Trp Thr Arg Asn

C25H37N9O7 (575.2816)

Trp Trp Ala Asn

C29H33N7O6 (575.2492)

Trp Trp Gly Lys

C30H37N7O5 (575.2856)

Trp Trp Gly Gln

C29H33N7O6 (575.2492)

Trp Trp Lys Gly

C30H37N7O5 (575.2856)

Trp Trp Asn Ala

C29H33N7O6 (575.2492)

Trp Trp Gln Gly

C29H33N7O6 (575.2492)

Trp Tyr Ala His

C29H33N7O6 (575.2492)

Trp Tyr His Ala

C29H33N7O6 (575.2492)

Tyr Ala His Trp

C29H33N7O6 (575.2492)

Tyr Ala Trp His

C29H33N7O6 (575.2492)

Tyr Glu His Lys

C26H37N7O8 (575.2703)

Tyr Glu Lys His

C26H37N7O8 (575.2703)

Tyr His Ala Trp

C29H33N7O6 (575.2492)

Tyr His Glu Lys

C26H37N7O8 (575.2703)

Tyr His Lys Glu

C26H37N7O8 (575.2703)

Tyr His Arg Thr

C25H37N9O7 (575.2816)

Tyr His Thr Arg

C25H37N9O7 (575.2816)

Tyr His Trp Ala

C29H33N7O6 (575.2492)

Tyr Lys Glu His

C26H37N7O8 (575.2703)

Tyr Lys His Glu

C26H37N7O8 (575.2703)

Tyr Arg His Thr

C25H37N9O7 (575.2816)

Tyr Arg Thr His

C25H37N9O7 (575.2816)

Tyr Thr His Arg

C25H37N9O7 (575.2816)

Tyr Thr Arg His

C25H37N9O7 (575.2816)

Tyr Trp Ala His

C29H33N7O6 (575.2492)

Tyr Trp His Ala

C29H33N7O6 (575.2492)

DTVIE

C24H41N5O11 (575.2802)

LLESD

C24H41N5O11 (575.2802)

Mauritine A

C32H41N5O5 (575.3108)

A natural product found in Ziziphus apetala.

3,14,25-Trihydroxy-2,10,13,21,24-pentaoxo-3,9,14,20,25-pentaazatriacontan-30-oic acid

C25H45N5O10 (575.3166)

LPC 20:4;O2

C28H50NO9P (575.3223)

C.I. 44085

C38H42ClN3 (575.3067)

Tandospirone Citrate

C27H37N5O9 (575.2591)

D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist Tandospirone citrate is a potent and selective 5-HT1A receptor partial agonist (Ki = 27 nM) that displays selectivity over SR-2, SR-1C, α1, α2, D1 and D2 receptors (Ki values ranging from 1300-41000 nM). IC50 Value: 27±5 nM(Ki) [1] Target: 5-HT1A in vitro: Tandospirone is most potent at the 5-HT1A receptor, displaying a Ki value of 27 +/- 5 nM. The agent is approximately two to three orders of magnitude less potent at 5-HT2, 5-HT1C, alpha 1-adrenergic, alpha 2-adrenergic, and dopamine D1 and D2 receptors (Ki values ranging from 1300 to 41000 nM). Tandospirone is essentially inactive at 5-HT1B receptors; 5-HT uptake sites; beta-adrenergic, muscarinic cholinergic, and benzodiazepine receptors [1]. 3H-SM-3997 bound rapidly, reversibly and in a saturable manner with high affinity to rat brain hippocampal membranes (Kd = 9.4 nM, Bmax = 213 fmol/mg protein) [2]. in vivo: Chronic treatment with tandospirone, at 0.2 and 1.0mg/kg/day, but not 2.0mg/kg/day, attenuated footshock stress-induced eLAC elevation in the mPFC [3]. Rats were acutely administered tandospirone (0, 0.1, and 1 mg/kg, i.p.). Tandospirone decreased the number of premature responses, an index of impulsive action, in a dose-dependent manner [4]. Toxicity: It is not believed to be addictive but it is known to produce mild withdrawal effects (e.g. anorexia) after abrupt discontinuation.

Fmoc-NH-PEG6-CH2CH2COOH

C30H41NO10 (575.273)

H-Pro-Phe-Arg-AMC acetate salt

C30H37N7O5 (575.2856)

(4r)-3-{(2s,3s)-2-Hydroxy-3-[(3-Hydroxy-2-Methylbenzoyl)amino]-4-Phenylbutanoyl}-5,5-Dimethyl-N-(2-Methylbenzyl)-1,3-Thiazolidine-4-Carboxamide

C32H37N3O5S (575.2454)

Garamycin solution

C21H45N5O11S (575.2836)

PC(2:0/18:2(10E,12Z)+=O(9))

C28H50NO9P (575.3223)

PC(18:2(10E,12Z)+=O(9)/2:0)

C28H50NO9P (575.3223)

PC(2:0/18:2(9Z,11E)+=O(13))

C28H50NO9P (575.3223)

PC(18:2(9Z,11E)+=O(13)/2:0)

C28H50NO9P (575.3223)

[(2R)-3-acetyloxy-2-[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C28H50NO9P (575.3223)

[(2R)-2-acetyloxy-3-[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C28H50NO9P (575.3223)

[(2R)-3-acetyloxy-2-[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C28H50NO9P (575.3223)

N-[1-[[5-(diaminomethylideneamino)-2-[(4-methyl-2-oxochromen-7-yl)amino]pentanoyl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide

C30H37N7O5 (575.2856)

Epimauritine A

C32H41N5O5 (575.3108)

A natural product found in Ziziphus apetala.

Bromocriptine Impurity B

C32H41N5O5 (575.3108)

5alpha-(Butan-2-yl)-12-hydroxy-3,6,18-trioxo-2-(propan-2-yl)ergotaman

C32H41N5O5 (575.3108)

N-[[(3R,9R,10S)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

(4S,5S)-4-[[2-(azidomethyl)phenyl]methyl]-2-[4-(3-hydroxypropoxy)phenyl]-5-phenyl-N-(phenylmethyl)-5H-oxazole-4-carboxamide

C34H33N5O4 (575.2532)

N-[(3R,9R,10S)-9-[(dimethylamino)methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[[(3R,9S,10S)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-(1-tetrazolyl)acetamide

C27H32F3N7O4 (575.2468)

N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-(1-tetrazolyl)acetamide

C27H32F3N7O4 (575.2468)

N-[(3S,9R,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-(phenylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]methanesulfonamide

C30H45N3O6S (575.3029)

N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-(1-tetrazolyl)acetamide

C27H32F3N7O4 (575.2468)

N-[[(3R,9S,10R)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[[(3S,9R,10R)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[[(3R,9R,10R)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[[(3R,9R,10R)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[(3R,9S,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-(phenylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]methanesulfonamide

C30H45N3O6S (575.3029)

N-[[(3R,9S,10S)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[(3S,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-(phenylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]methanesulfonamide

C30H45N3O6S (575.3029)

N-[(3S,9S,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-(phenylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]methanesulfonamide

C30H45N3O6S (575.3029)

N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[[(4-methoxyanilino)-oxomethyl]-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide

C31H37N5O6 (575.2744)

1-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-9-[[(1-naphthalenylamino)-oxomethyl]amino]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea

C32H41N5O5 (575.3108)

N-[(3R,9R,10S)-9-[(dimethylamino)methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[(3S,9R,10S)-9-[(dimethylamino)methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[(3R,9S,10S)-9-[(dimethylamino)methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[(3S,9S,10R)-9-[(dimethylamino)methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[(3S,9R,10R)-9-[(dimethylamino)methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

1-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-9-[[(1-naphthalenylamino)-oxomethyl]amino]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea

C32H41N5O5 (575.3108)

N-[(3R,9R,10R)-9-[(dimethylamino)methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[(3R,9R,10R)-9-[(dimethylamino)methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[(3S,9S,10S)-9-[(dimethylamino)methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[(3S,9R,10S)-9-[(dimethylamino)methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

(5S,6R,9R)-5-methoxy-N-(2-methoxyphenyl)-3,6,9-trimethyl-2-oxo-14-[[oxo(2-pyridinyl)methyl]amino]-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-8-carboxamide

C31H37N5O6 (575.2744)

N-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylbenzenesulfonamide

C32H37N3O5S (575.2454)

N-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylbenzenesulfonamide

C32H37N3O5S (575.2454)

N-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylbenzenesulfonamide

C32H37N3O5S (575.2454)

N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-(1-tetrazolyl)acetamide

C27H32F3N7O4 (575.2468)

N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-(1-tetrazolyl)acetamide

C27H32F3N7O4 (575.2468)

N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-(1-tetrazolyl)acetamide

C27H32F3N7O4 (575.2468)

N-[[(3R,9R,10S)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[[(3S,9R,10S)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[[(3S,9S,10R)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[(3S,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-(phenylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]methanesulfonamide

C30H45N3O6S (575.3029)

N-[[(3S,9S,10R)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[(3S,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-(phenylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]methanesulfonamide

C30H45N3O6S (575.3029)

N-[(3R,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-(phenylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]methanesulfonamide

C30H45N3O6S (575.3029)

N-[(3R,9R,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-(phenylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]methanesulfonamide

C30H45N3O6S (575.3029)

N-[[(3S,9R,10S)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[(3R,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-(phenylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]methanesulfonamide

C30H45N3O6S (575.3029)

N-[[(3S,9S,10S)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[(3S,9R,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-(phenylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]methanesulfonamide

C30H45N3O6S (575.3029)

N-[[(3S,9R,10R)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[(3R,9R,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-(phenylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]methanesulfonamide

C30H45N3O6S (575.3029)

N-[[(3S,9S,10S)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[(3R,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-(phenylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]methanesulfonamide

C30H45N3O6S (575.3029)

N-[(3S,9S,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-(phenylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]methanesulfonamide

C30H45N3O6S (575.3029)

N-[(3S,9R,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-(phenylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]methanesulfonamide

C30H45N3O6S (575.3029)

N-[(3R,9S,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-(phenylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]methanesulfonamide

C30H45N3O6S (575.3029)

N-[[(3R,9S,10R)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[(3R,9S,10S)-9-[(dimethylamino)methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

1-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-9-[[(1-naphthalenylamino)-oxomethyl]amino]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea

C32H41N5O5 (575.3108)

1-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-9-[[(1-naphthalenylamino)-oxomethyl]amino]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea

C32H41N5O5 (575.3108)

N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[[(4-methoxyanilino)-oxomethyl]-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide

C31H37N5O6 (575.2744)

N-[(3R,9S,10R)-9-[(dimethylamino)methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[(3S,9S,10S)-9-[(dimethylamino)methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[(3S,9R,10R)-9-[(dimethylamino)methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

1-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-9-[[(1-naphthalenylamino)-oxomethyl]amino]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea

C32H41N5O5 (575.3108)

N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[[(4-methoxyanilino)-oxomethyl]-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide

C31H37N5O6 (575.2744)

N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-(1-tetrazolyl)acetamide

C27H32F3N7O4 (575.2468)

N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-(1-tetrazolyl)acetamide

C27H32F3N7O4 (575.2468)

N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-fluorobenzenesulfonamide

C30H42FN3O5S (575.2829)

N-[(3R,9S,10R)-9-[(dimethylamino)methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[(3S,9S,10R)-9-[(dimethylamino)methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C30H45N3O6S (575.3029)

N-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylbenzenesulfonamide

C32H37N3O5S (575.2454)

N-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylbenzenesulfonamide

C32H37N3O5S (575.2454)

N-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylbenzenesulfonamide

C32H37N3O5S (575.2454)

N-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylbenzenesulfonamide

C32H37N3O5S (575.2454)

Lnaps 16:3/N-5:0

C27H46NO10P (575.2859)

Lnaps 3:0/N-18:3

C27H46NO10P (575.2859)

Lnaps 5:0/N-16:3

C27H46NO10P (575.2859)

Lnaps 18:3/N-3:0

C27H46NO10P (575.2859)

2-amino-3-[hydroxy-[2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxy-3-propanoyloxypropoxy]phosphoryl]oxypropanoic acid

C27H46NO10P (575.2859)

2-amino-3-[[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-pentanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C27H46NO10P (575.2859)

LSM-6455

C32H41N5O5 (575.3108)

PE 14:1/8:3;O2

C27H46NO10P (575.2859)

PE 18:3/4:1;O2

C27H46NO10P (575.2859)

PE 22:4;O2

C27H46NO10P (575.2859)

LNAPS 20:4;O

C26H42NO11P (575.2495)

LNAPS 21:3

C27H46NO10P (575.2859)

LPS 20:5;O2

C26H42NO11P (575.2495)

PS 17:2/4:1

C27H46NO10P (575.2859)

PS 21:3

C27H46NO10P (575.2859)

ST 29:5;O7;Gly

C31H45NO9 (575.3094)

ST 18:1;O8;HexNAc

C26H41NO13 (575.2578)

ST 19:0;O7;HexNAc

C27H45NO12 (575.2942)

ST 22:5;O5;HexNAc

C30H41NO10 (575.273)

ST 23:4;O4;HexNAc

C31H45NO9 (575.3094)

ST 25:2;O7;Tau

C27H45NO10S (575.2764)

ST 26:1;O6;Tau

C28H49NO9S (575.3128)

ST 28:7;O5;Tau

C30H41NO8S (575.2553)

ST 29:6;O4;Tau

C31H45NO7S (575.2917)

Z-Phe-Arg-pNA

C29H33N7O6 (575.2492)

Z-Phe-Arg-pNA is a substrate of Cathepsin L[1].

(4r,7r)-n-[(1s,2s,4r)-2-hydroxy-4-isopropyl-5,8-dioxo-7-(sec-butyl)-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C32H41N5O5 (575.3108)

(4s,7r)-n-[(1s,2s,4r,7s)-2-hydroxy-4-isopropyl-7-(2-methylpropyl)-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C32H41N5O5 (575.3108)

(1s,3s,4ar,5s,6r,6ar,10as,10bs)-6-(benzoyloxy)-5-hydroxy-4a,6a,7,10b-tetramethyl-5'-oxo-2,5,6,9,10,10a-hexahydro-1h-spiro[naphtho[2,1-b]pyran-3,3'-oxolan]-1-yl pyridine-3-carboxylate

C33H37NO8 (575.2519)

n-[2-hydroxy-4-isopropyl-7-(2-methylpropyl)-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C32H41N5O5 (575.3108)

α-ergokryptinine

C32H41N5O5 (575.3108)

{"Ingredient_id": "HBIN015506","Ingredient_name": "\u03b1-ergokryptinine","Alias": "NA","Ingredient_formula": "C32H41N5O5","Ingredient_Smile": "CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=CNC7=CC=CC(=C67)C5=C4)C)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "7237","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

6-(benzoyloxy)-5-hydroxy-4a,6a,10b-trimethyl-7-methylidene-5'-oxo-octahydrospiro[naphtho[2,1-b]pyran-3,3'-oxolan]-1-yl pyridine-3-carboxylate

C33H37NO8 (575.2519)

(4s,7r)-n-[(1s,2s,4r,7s)-4,7-diisopropyl-2-methoxy-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C32H41N5O5 (575.3108)

(2s)-n-[(1s)-1-({3-[(2s,5s)-3,6-dihydroxy-5-[3-(n-hydroxyformamido)propyl]-2,5-dihydropyrazin-2-yl]propyl}(hydroxy)carbamoyl)-2-hydroxyethyl]-2-[(1-hydroxyethylidene)amino]-5-(n-hydroxyformamido)pentanimidic acid

C22H37N7O11 (575.2551)

2-[(2e)-1-[(1-carboxy-2-phenylethyl)-c-hydroxycarbonimidoyl]-10-oxoheptadec-2-en-1-yl]-2-hydroxybutanedioic acid

C31H45NO9 (575.3094)

(4r,7r)-n-[(1s,2s,4r,7s)-2-hydroxy-4-isopropyl-7-(2-methylpropyl)-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C32H41N5O5 (575.3108)

(4r,7r)-n-[(1s,2s,4r,7s)-7-[(2s)-butan-2-yl]-2-hydroxy-4-isopropyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C32H41N5O5 (575.3108)

n-{1-[(3-{3,6-dihydroxy-5-[3-(n-hydroxyformamido)propyl]-2,5-dihydropyrazin-2-yl}propyl)(hydroxy)carbamoyl]-2-hydroxyethyl}-2-[(1-hydroxyethylidene)amino]-5-(n-hydroxyformamido)pentanimidic acid

C22H37N7O11 (575.2551)

n-{1-[(13z)-10-benzyl-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-3-methyl-1-oxobutan-2-yl}-2-(dimethylamino)propanimidic acid

C32H41N5O5 (575.3108)

(4r,7r)-n-[(1s,2s,4r,7s)-7-[(2r)-butan-2-yl]-2-hydroxy-4-isopropyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C32H41N5O5 (575.3108)

(1s,3s,4ar,5s,6r,6ar,10as,10bs)-6-(benzoyloxy)-5-hydroxy-4a,6a,10b-trimethyl-7-methylidene-5'-oxo-octahydrospiro[naphtho[2,1-b]pyran-3,3'-oxolan]-1-yl pyridine-3-carboxylate

C33H37NO8 (575.2519)

(2s)-n-[(2s)-1-[(3s,7s,10s)-10-benzyl-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-3-methyl-1-oxobutan-2-yl]-2-(dimethylamino)propanimidic acid

C32H41N5O5 (575.3108)

n-{4,7-diisopropyl-2-methoxy-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl}-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C32H41N5O5 (575.3108)

n-[2-({[(1r,15s,17r,18r,19s,20s)-6,18-dimethoxy-19-(methoxycarbonyl)-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8-tetraen-17-yl]oxy}carbonyl)phenyl]ethanimidic acid

C32H37N3O7 (575.2631)

(2-{2-[(1s,2s,4ar)-1,2,5,5-tetramethyl-2,3,4,4a,6,7-hexahydronaphthalen-1-yl]ethyl}-5-{1-[2-(3h-imidazol-4-yl)ethyl]-2,5-dioxopyrrol-3-yl}pentyl)oxysulfonic acid

C30H45N3O6S (575.3029)

n-(1-{10-benzyl-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl}-3-methyl-1-oxobutan-2-yl)-2-(dimethylamino)propanimidic acid

C32H41N5O5 (575.3108)

(4r,7r)-n-[(1s)-2-hydroxy-4-isopropyl-7-(2-methylpropyl)-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C32H41N5O5 (575.3108)

(2r,5s,8s,11s)-3,9,12-trihydroxy-11-[(4-hydroxyphenyl)methyl]-2,5,8-tris(2-methylpropyl)-1,7-dioxa-4,10,13-triazacyclohexadeca-3,9,12-triene-6,16-dione

C30H45N3O8 (575.3206)

(2s)-n-[(2s)-1-[(3s,7s,10s,13z)-10-benzyl-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-3-methyl-1-oxobutan-2-yl]-2-(dimethylamino)propanimidic acid

C32H41N5O5 (575.3108)

3,12-dibenzyl-5,14,17-trihydroxy-15-(hydroxymethyl)-1,4,10,13,16-pentaazatricyclo[16.3.0.0⁶,¹⁰]henicosa-4,13,16-triene-2,11-dione

C31H37N5O6 (575.2744)

3,9,12-trihydroxy-11-[(4-hydroxyphenyl)methyl]-2,5,8-tris(2-methylpropyl)-1,7-dioxa-4,10,13-triazacyclohexadeca-3,9,12-triene-6,16-dione

C30H45N3O8 (575.3206)

[(2s)-2-{2-[(1s,2s,4ar)-1,2,5,5-tetramethyl-2,3,4,4a,6,7-hexahydronaphthalen-1-yl]ethyl}-5-{1-[2-(3h-imidazol-4-yl)ethyl]-2,5-dioxopyrrol-3-yl}pentyl]oxysulfonic acid

C30H45N3O6S (575.3029)

6-(benzoyloxy)-5-hydroxy-4a,6a,7,10b-tetramethyl-5'-oxo-2,5,6,9,10,10a-hexahydro-1h-spiro[naphtho[2,1-b]pyran-3,3'-oxolan]-1-yl pyridine-3-carboxylate

C33H37NO8 (575.2519)

(4r,7r)-n-[(1s,2s,4r,7r)-7-[(2s)-butan-2-yl]-2-hydroxy-4-isopropyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C32H41N5O5 (575.3108)

(7r)-n-[(1s,2s,4r,7s)-7-butyl-2-hydroxy-4-isopropyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C32H41N5O5 (575.3108)

(3s,6s,12s,15s,18s)-3,12-dibenzyl-5,14,17-trihydroxy-15-(hydroxymethyl)-1,4,10,13,16-pentaazatricyclo[16.3.0.0⁶,¹⁰]henicosa-4,13,16-triene-2,11-dione

C31H37N5O6 (575.2744)

(4r,7r)-n-[(1s,2s,4r,7s)-4,7-diisopropyl-2-methoxy-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid

C32H41N5O5 (575.3108)